Mika Yamanaka-Takaichi

Dr. Mika Yamanaka-Takaichi

Osaka City University Graduate School of Medicine

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MYMika Yamanaka-Takaichi
Mika Yamanaka-Takaichi
YMYukari Mizukami
Yukari Mizukami
KSKoji Sugawara
Koji Sugawara
KSKishiko Sunami
Kishiko Sunami
YTYuichi Teranishi
Yuichi Teranishi
Daisuke TsurutaDaisuke Tsuruta
Daisuke Tsuruta
Psychological stress exacerbates mast cell (MC)-dependent inflammation, including nasal allergy, but the underlying mechanisms are not thoroughly understood. Because the key stress-mediating neurohormone, corticotropin-releasing hormone (CRH), induces human skin MC degranulation, we hypothesized that CRH may be a key player in stress-aggravated nasal allergy. In the current study, we probed this hypothesis in human nasal mucosa MCs (hM-MCs) in situ using nasal polyp organ culture and tested whether CRH is required for murine M-MC activation by perceived stress in vivo. CRH stimulation significantly increased the number of hM-MCs, stimulated both their degranulation and proliferation ex vivo, and increased stem cell factor (SCF) expression in human nasal mucosa epithelium. CRH also sensitized hM-MCs to further CRH stimulation and promoted a pro-inflammatory hM-MC phenotype. The CRH-induced increase in hM-MCs was mitigated by co-administration of CRH receptor type 1 (CRH-R1)-specific antagonist antalarmin, CRH-R1 small interfering RNA (siRNA), or SCF-neutralizing antibody. In vivo, restraint stress significantly increased the number and degranulation of murine M-MCs compared with sham-stressed mice. This effect was mitigated by intranasal antalarmin. Our data suggest that CRH is a major activator of hM-MC in nasal mucosa, in part via promoting SCF production, and that CRH-R1 antagonists such as antalarmin are promising candidate therapeutics for nasal mucosa neuroinflammation induced by perceived stress.

22 September 2024 in International Journal of Dermatology
Verified
Journal Article
Closed access
MYMika Yamanaka-Takaichi
Mika Yamanaka-Takaichi
SNSoheila Nadalian
Soheila Nadalian
ELEdward Loftus
Edward Loftus
EEEric C. Ehman
Eric C. Ehman
ATAustin Todd
Austin Todd
AAAfsaneh Alavi
Afsaneh Alavi

15 February 2019 in The Journal of Dermatology
Verified
Journal Article
Closed access
MYMika Yamanaka-Takaichi
Mika Yamanaka-Takaichi
TOToshiyuki Ozawa
Toshiyuki Ozawa
NKNao Kusutani
Nao Kusutani
JSJunko Sowa‐Osako
Junko Sowa‐Osako
MTMasaru Tanaka
Masaru Tanaka
HSHiroshi Sakai
Hiroshi Sakai

23 June 2023 in Dermatology
Verified
Journal Article
Closed access
PDF file
MYMika Yamanaka-Takaichi
Mika Yamanaka-Takaichi
LRLaura E. Raffals
Laura E. Raffals
EEEric C. Ehman
Eric C. Ehman
EJEdward V. Loftus Jr.
Edward V. Loftus Jr.
AAAfsaneh Alavi
Afsaneh Alavi
Background: Hidradenitis suppurativa (HS) and inflammatory bowel disease (IBD) have been reported to have a wide variety of overlaps in their pathogenesis, laboratory findings, and histopathology. These two diseases can form draining tunnels and are difficult to differentiate, particularly from fistulizing lesions in the perianal area. Objective: This retrospective study of HS and IBD patients with perianal lesions sought to analyze the anemia and systemic inflammation biomarkers in these disease groups. Methods: A retrospective chart review was conducted on the laboratory findings of a total of 212 patients with perianal disease – 72 with HS, 78 with IBD, and 62 with both HS and IBD – who were evaluated at Mayo Clinic between 1998 and 2021. Results: In the HS group, 45.8% of males and females were anemic, compared to 58.1% of males and 73.5% of females in the IBD group. The HS + IBD group had the highest prevalence of anemia and the lowest hemoglobin levels. The odds ratio for being anemic was 2.19 for the IBD group and 4.05 for the IBD + HS group compared to the HS group. Monocyte/lymphocyte ratio (MLR) and platelet/lymphocyte ratio (PLR) were significantly higher in the IBD group, whereas neutrophil/lymphocyte ratio (NLR) was significantly higher in the IBD + HS group. Conclusion: Our data show for the first time the prevalence of anemia in patients with HS and IBD who have perianal lesions. In addition, noninvasive biomarkers using complete blood counts such as MLR, PLR, and NLR could be useful not only in differentiating perianal HS from fistulizing perianal IBD but also in selecting treatment.

4 July 2024 in The Journal of Dermatology
Verified
Journal Article
Closed access
RORina Obata
Rina Obata
HIHisayoshi Imanishi
Hisayoshi Imanishi
YNYasuhiro Nakashima
Yasuhiro Nakashima
MYMika Yamanaka-Takaichi
Mika Yamanaka-Takaichi
AIAkiko Imanishi
Akiko Imanishi
DTDaisuke Tsuruta
Daisuke Tsuruta

25 July 2025 in Dermatology
Verified
Journal Article
Closed access
MYMika Yamanaka-Takaichi
Mika Yamanaka-Takaichi
MYMariana Yalon
Mariana Yalon
ELEdward V. Loftus
Edward V. Loftus
AGAnna B. Grimaldo
Anna B. Grimaldo
ATAustin Todd
Austin Todd
EEEric C. Ehman
Eric C. Ehman
Introduction: Both hidradenitis suppurativa (HS) and Crohn disease (CD) are characterized by suppuration and granulomatous inflammation, which may result in formation of tunnels, sinus tracts, or fistulas. We sought to determine the differences in characteristics of fistulizing perianal CD vs. perianal HS on magnetic resonance imaging (MRI). Methods: This retrospective cohort study included patients diagnosed with CD, HS, or both diseases who underwent medical examination at the Mayo Clinic between January 1, 1998, and July 31, 2021. We further selected patients who had documented perianal lesions and underwent pelvic MRI. Two abdominal radiologists blinded to clinical diagnosis reviewed the MR images for the presence or absence of 10 characteristics. For characteristics that differed significantly between patients with CD and HS, odds ratios were calculated. A radiomics-based MRI scoring system was constructed according to the odds ratios and was validated. Results: On MRI, significantly more patients in the HS group (n = 49) than the CD group (n = 74) had subcutaneous tunnels (35% vs. 4%; p < 0.001), soft-tissue inflammation of subcutaneous tissue and skin (35% vs. 5%; p < 0.001), and inguinal lymphadenopathy (65% vs. 45%; p = 0.02). Significantly more patients in the CD group than the HS group had transsphincteric fistula (64% vs. 35%; p = 0.002), intersphincteric fistula (58% vs. 29%; p = 0.001), mesorectal lymphadenopathy (26% vs. 4%; p = 0.002), and rectal inflammation (32% vs. 12%; p = 0.01). The proposed MRI scoring system for distinguishing HS from CD had a sensitivity of 0.77, specificity of 0.80, and area under the curve of 0.84. Conclusion: MRI may be a valuable tool in distinguishing perianal draining tunnels in HS from fistulizing perianal CD. The MRI scoring system we created could help in the clinical decision-making process. Combining MRI with other investigational and clinical findings may improve diagnostic accuracy for these challenging perianal diseases.